Promoter methylation of the retinoic acid receptor beta2 (RARβ2) is associated with increased risk of breast cancer: A prisma compliant meta-analysis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Fang, Cheng ^a   Jian, Zhi Yuan ^b   Shen, Xian Feng ^b   Wei, Xue Mei ^c   Yu, Guo Zheng ^a   Zeng, Xian Tao ^a  

^a WUHAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; UNCLASSIFIED DRUG; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR, BETA2, HUMAN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER STAGING; HISTOLOGY; HUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METHYLATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; BREAST TUMOR; DNA METHYLATION; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; PATHOLOGY;

BREAST NEOPLASMS; DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, RETINOIC ACID;

EID: 84948672153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140329     Document Type: Article

References (49)

1. Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P. Breast cancer statistics and markers. J Cancer Res Ther. 2014;10(3):506-11. Epub 2014/10/15. JCanResTher-2014-10-3-506-137927 [pii] PMID: 25313729.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. Epub 2005/03/12. 55/2/74 [pii]. PMID: 15761078.
3. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62. Epub 2013/10/12. doi: 10.3322/caac.21203 PMID: 24114568.
4. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089-96. Epub 1998/04/17. doi: 10.1056/NEJM199804163381601 PMID: 9545356.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-54. Epub 2003/11/25. doi: 10.1056/NEJMra023075 349/21/2042 [pii]. PMID: 14627790.
6. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68(20):8541-6. Epub 2008/10/17. 68/20/8541 [pii] doi: 10.1158/0008-5472. CAN-08-1171 PMID: 18922929.
7. Rykova EY, Tsvetovskaya GA, Sergeeva GI, Vlassov VV, Laktionov PP. Methylation-based analysis of circulating DNA for breast tumor screening. Ann N Y Acad Sci. 2008;1137:232-5. Epub 2008/10/08. NYAS1137021 [pii] doi: 10.1196/annals.1448.021 PMID: 18837953.
8. Hayashi K, Goodison S, Urquidi V, Tarin D, Lotan R, Tahara E. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4. Int J Oncol. 2003;22(3):623-9. Epub 2003/02/13. PMID: 12579317.
9. Pappas JJ, Toulouse A, Hebert J, Fetni R, Bradley WE. Allelic methylation bias of the RARB2 tumor suppressor gene promoter in cancer. Genes Chromosomes Cancer. 2008;47(11):978-93. Epub 2008/07/30. doi: 10.1002/gcc.20603 PMID: 18663751.
10. Tsou HC, Yao YJ, Xie XX, Ping XL, Peacocke M. Repression of transactivation of the retinoic acid receptor beta2 promoter in human breast cancer cells. Exp Cell Res. 1998;245(1):221-7. Epub 1998/11/26. S0014-4827(98)94268-9 [pii] doi: 10.1006/excr.1998.4268 PMID: 9828119.
11. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 1994;54(13):3580-7. Epub 1994/07/01. PMID: 8012985.
12. Zhang XK, Liu Y, Lee MO, Pfahl M. A specific defect in the retinoic acid response associated with human lung cancer cell lines. Cancer Res. 1994;54(21):5663-9. Epub 1994/11/01. PMID: 7923214.
13. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst. 2000;92(10):826-32. Epub 2000/05/18. PMID: 10814678.
14. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol. 2003;16(11):1095-101. Epub 2003/11/14. doi: 10.1097/01. MP.0000095782.79895. E2 PMID: 14614048.
15. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, et al. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer. 2010;10:378. Epub 2010/07/21. doi: 10.1186/1471-2407-10-378 1471-2407-10-378 [pii]. PMID: 20642860; PubMed Central PMCID: PMCPMC2914707.
16. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene. 2000;19(12):1556-63. Epub 2000/03/29. doi: 10.1038/sj.onc.1203456 PMID: 10734315.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. Epub 2009/07/23. doi: 10.1136/bmj.b2535 bmj.b2535 [pii]. PMID: 19622551; PubMed Central PMCID: PMCPMC2714657.
18. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83(4):803-19. Epub 2003/07/24. S0039-6109 (03) 00034-3 [pii] doi: 10.1016/S0039-6109 (03) 00034-3 PMID: 12875597.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58. Epub 2002/07/12. doi: 10.1002/sim.1186 PMID: 12111919.
20. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 2012;19(9):3107-15. Epub 2012/03/28. doi: 10.1245/s10434-012-2323-5 PMID: 22451234.
21. Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res. 2004;10(16):5349-54. Epub 2004/08/26. doi: 10.1158/1078-0432. CCR-04-0555 10/16/5349 [pii]. PMID: 15328171.
22. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res. 2005;11(1):166-72. Epub 2005/01/27. 11/1/166 [pii]. PMID: 15671542.
23. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol. 2006;24(26):4262-9. Epub 2006/08/16. JCO.2005.01.3516 [pii] doi: 10.1200/JCO.2005.01.3516 PMID: 16908936.
24. Li S, Rong M, Iacopetta B. DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett. 2006;237(2):272-80. Epub 2005/07/21. S0304-3835 (05) 00556-2 [pii] doi: 10.1016/j.canlet.2005.06.011 PMID: 16029926.
25. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, et al. Cellfree and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumourrelated gene methylation. Br J Cancer. 2006;94(10):1492-5. Epub 2006/04/28. 6603117 [pii] doi: 10. 1038/sj.bjc.6603117 PMID: 16641902; PubMed Central PMCID: PMC2361269.
26. Bagadi SA, Prasad CP, Kaur J, Srivastava A, Prashad R, Gupta SD, et al. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sci. 2008;82(25-26):1288-92. Epub 2008/06/10. S0024-3205 (08) 00196-3 [pii] doi: 10. 1016/j.lfs.2008.04.020 PMID: 18538349.
27. Jeronimo C, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat. 2008;109(1):27-34. Epub 2007/06/06. doi: 10.1007/s10549-007-9620-x PMID: 17549626.
28. Tao MH, Shields PG, Nie J, Millen A, Ambrosone CB, Edge SB, et al. DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat. 2009;114(3):559-68. Epub 2008/05/09. doi: 10.1007/s10549-008-0028-z PMID: 18463976.
29. Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, et al. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther. 2009;8(23):2252-9. Epub 2009/10/16. 10133 [pii]. PMID: 19829046.
30. Brooks JD, Cairns P, Shore RE, Klein CB, Wirgin I, Afanasyeva Y, et al. DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. Cancer Epidemiol. 2010;34(6):717-23. Epub 2010/07/16. S1877-7821 (10) 00098-6 [pii]. PMID: 20627767; PubMed Central PMCID: PMCPMC2956002.
31. Jing F, Yuping W, Yong C, Jie L, Jun. L, Xuanbing T, et al. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol. 2010;31(4):321-31. Epub 2010/05/22. doi: 10.1007/s13277-010-0040-x PMID: 20490964.
32. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, et al. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol. 2010;136(2):203-10. Epub 2009/08/07. doi: 10.1007/s00432-009-0649-6 PMID: 19657672.
33. Pirouzpanah S, Taleban FA, Atri M, Abadi AR, Mehdipour P. The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer. Cancer Causes Control. 2010;21(12):2101-11. Epub 2010/08/17. doi: 10.1007/s10552-010-9629-z PMID: 20711807.
34. Swellam M, Abdelmaksoud MD, Sayed Mahmoud M, Ramadan A, Abdel-Moneem W, Hefny MM. Aberrant methylation of APC and RARbeta2 genes in breast cancer patients. IUBMB Life. 2015;67(1):61-8. Epub 2015/02/17. doi: 10.1002/iub.1346 PMID: 25684670.
35. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res. 2005;11(6):2156-62. Epub 2005/03/25. 11/6/2156 [pii] doi: 10.1158/1078-0432. CCR-04-1810 PMID: 15788661.
36. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 2001;357(9265):1335-6. Epub 2001/05/10. S0140673600045013 [pii]. PMID: 11343741.
37. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003;107(6):970-5. Epub 2003/11/06. doi: 10.1002/ijc.11508 PMID: 14601057.
38. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2-10. Epub 2015/01/17. doi: 10.1111/jebm.12141 PMID: 25594108.
39. Zeng XT, Leng WD, Zhang C, Liu J, Cao SY, Huang W. Meta-analysis on the association between toothbrushing and head and neck cancer. Oral Oncol. 2015;51(5):446-51. Epub 2015/03/11. doi: 10. 1016/j.oraloncology.2015.02.095 S1368-8375 (15) 00126-8 [pii]. PMID: 25753558.
40. Zeng XT, Luo W, Geng PL, Guo Y, Niu YM, Leng WD. Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis. BMC Cancer. 2014;14:469. Epub 2014/06/28. doi: 10.1186/1471-2407-14-469 1471-2407-14-469 [pii]. PMID: 24969046; PubMed Central PMCID: PMCPMC4094444.
41. Zeng XT, Liu DY, Kwong JS, Leng WD, Xia LY, Mao M. Meta-Analysis of Association Between Interleukin-1beta C-511T Polymorphism and Chronic Periodontitis Susceptibility. J Periodontol. 2015;86(6):812-9. Epub 2015/03/06. doi: 10.1902/jop. 2015.140698 PMID: 25741583.
42. Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, Garrett-Meyer E, et al. A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women. Cancer Biol Ther. 2007;6(7):1114-20. Epub 2007/07/06. 4331 [pii] doi: 10.4161/cbt.6.7.4331 PMID: 17611401.
43. van Hoesel AQ, van de Velde CJ, Kuppen PJ, Putter H, de Kruijf EM, van Nes JG, et al. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res Treat. 2012;131(3):859-69. Epub 2011/04/12. doi: 10.1007/s10549-011-1485-3 PMID: 21479925.
44. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62(9):2455-61. Epub 2002/05/01. PMID: 11980632.
45. Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One. 2012;7(5):e37928. Epub 2012/06/16. doi: 10.1371/journal. pone.0037928 PONE-D-12-03598 [pii]. PMID: 22701537; PubMed Central PMCID: PMCPMC3365111.
46. Bistulfi G, Pozzi S, Ren M, Rossetti S, Sacchi N. A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk. Cancer Res. 2006;66(21):10308-14. Epub 2006/11/03. 66/21/10308 [pii] doi: 10.1158/0008-5472. CAN-06-1052 PMID: 17079450.
47. Ren M, Pozzi S, Bistulfi G, Somenzi G, Rossetti S, Sacchi N. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol. 2005;25(23):10591-603. Epub 2005/11/17. 25/23/10591 [pii] doi: 10.1128/MCB.25.23.10591-10603.2005 PMID: 16287870; PubMed Central PMCID: PMCPMC1291229.
48. Corlazzoli F, Rossetti S, Bistulfi G, Ren M, Sacchi N. Derangement of a factor upstream of RARalpha triggers the repression of a pleiotropic epigenetic network. PLoS One. 2009;4(1):e4305. Epub 2009/01/29. doi: 10.1371/journal.pone.0004305 PMID: 19173001; PubMed Central PMCID: PMCPMC2627936.
49. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122(6):835-47. Epub 2005/09/24. S0092-8674 (05) 00694-X [pii] doi: 10.1016/j.cell.2005.07.003 PMID: 16179254.